TrialClinical cancer research : an official journal of the American Association for Cancer Research2014

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Hartmut Koeppen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.